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Background: Erectile dysfunction after prostate radiation therapy remains an ongoing challenge and critical quality
of life issue. Given the higher dose of radiation per fraction using stereotactic body radiation therapy (SBRT) there is
concern that post-SBRT impotency would be higher than conventional radiation therapy approaches. This study
sought to evaluate potency preservation and sexual function following SBRT for prostate cancer.
Methods: Between February 2008 and March 2011, 216 men with clinically localized prostate cancer were treated
definitively with SBRT monotherapy at Georgetown University Hospital. Potency was defined as the ability to have
an erection firm enough for intercourse with or without sexual aids while sexual activity was defined as the ability
to have an erection firm enough for masturbation and foreplay. Patients who received androgen deprivation therapy
(ADT) were excluded from this study. Ninety-seven hormone-naïve men were identified as being potent at the initiation
of therapy and were included in this review. All patients were treated to 35–36.25 Gy in 5 fractions delivered with the
CyberKnife Radiosurgical System (Accuray). Prostate specific antigen (PSA) and total testosterone levels were obtained
pre-treatment, every 3 months for the first year and every 6 months for the subsequent year. Sexual function was
assessed with the Sexual Health Inventory for Men (SHIM), the Expanded Prostate Index Composite (EPIC)-26 and
Utilization of Sexual Medication/Device questionnaires at baseline and all follow-up visits.
Results: Ninety-seven men (43 low-, 50 intermediate- and 4 high-risk) at a median age of 68 years (range, 48–82 years)
received SBRT. The median pre-treatment PSA was 5.9 ng/ml and the minimum follow-up was 24 months. The median
pre-treatment total serum testosterone level was 11.4 nmol/L (range, 4.4-27.9 nmol/L). The median baseline SHIM was
22 and 36% of patients utilized sexual aids prior to treatment. Although potency rates declined following treatment: 100%
(baseline); 68% (6 months); 62% (12 months); 57% (18 months) and 54.4% (24 months), 78% of previously potent patients
had erections sufficient for sexual activity at 24 months post-treatment. Overall sexual aid utilization increased from 36%
at baseline to 49% at 24 months. Average EPIC sexual scores showed a slow decline over the first two years following
treatment: 77.6 (baseline); 68.7 (6 months); 63.2 (12 months); 61.9 (18 months); 59.3 (24 months). All sexual functions
including orgasm declined with time. Prior to treatment, 13.4% of men felt their sexual function was a moderate to big
problem which increased to 26.7% two years post treatment. Post-treatment testosterone levels gradually decreased
with a median value at two year follow-up of 10.7 nmol/L. However, the average EPIC hormonal scores did not illustrate
a statistically significant difference two years post-treatment. Review of the radiation doses to the penile bulb in this
study, a potential marker of post-treatment sexual function, revealed that the dose was relatively low and at these low
doses the percentage of the penile bulb receiving 29.5 Gy did not correlate with the development of ED.
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Conclusions: Men undergoing SBRT monotherapy for prostate cancer report sexual outcomes comparable to those
reported for conventional radiation modalities within the first 24 months after treatment. Longer follow-up is required
to confirm the durability of these findings.
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Post-treatment sexual function is a primary determin-
ant of satisfaction following prostate radiotherapy [1,2].
Erectile dysfunction (ED) occurs commonly following
external beam radiation therapy (EBRT) and/or brachy-
therapy [3]. The incidence of ED is dependent on the
potency definition [4,5] and on the manner of data col-
lection (i.e. patient or physician reported) [6]. Patients
with radiation-induced impotence report a decrease in
the quality and reliability of erection, ability to reach
orgasm and overall ability to function sexually [7]. ED
develops months to years after radiation therapy without
recovery [2]. Patient characteristics such as a history of
baseline ED [8], older age [9], obesity, comorbidities and
pretreatment sexual aid usage may increase an individual’s
risk of radiation induced ED [10]. In addition, utilization
of androgen deprivation therapy (ADT) [2] and radiation-
induced hypogonadism [11] can adversely affect sexual
outcomes while post-treatment utilization of sexual aids
may enhance them [12-14].
The etiology of radiation induced ED is currently
unclear but may involve damage to the neurovascular
bundles (NVBs) [15], crura [16,17] and/or penile bulb
(PB) [16,18]. Thus treatment-related factors such as
the radiation dose to these adjacent sexual structures
may contribute to the incidence and severity of ED.
The risk of ED may be related to the volume of the
crura/penile bulb in the high dose area [16]. To
minimize ED, it is currently recommended that the
median dose to the penile bulb be limited to < 50 Gy
with conventionally fractionated EBRT [19]. Studies
have shown that advanced radiation technologies such
as intensity modulated radiation therapy (IMRT) may
decrease the dose to the crura/penile bulb and poten-
tially decrease ED [20,21].
The optimal radiation schedule for the treatment of
prostate cancer is under active clinical investigation.
Recent data suggest that large radiation fraction sizes
are radiobiologically favorable over lower fraction sizes
in prostate cancer [22,23]. The α/β for prostate cancer
may be as low as 1.5 Gy [22]. If the α/β for prostate
cancer is less than 3 Gy, which is generally the value
accepted for late sexual complications, the linear-quadratic
model predicts that delivering large radiation fraction
sizes will result in improved local control with a similar
rate of sexual function complications.SBRT is a safe and effective treatment for clinically
localized prostate cancer [24-26]. The use of large fraction
sizes in SBRT offers the potential radiobiological bene-
fits of hypofractionation and potentially may minimize
radiation-associated ED by reducing the volume of critical
structures receiving high radiation doses. The CyberKnife
robotic radiosurgical system uses image guidance to track
implanted fiducials to account for intrafraction prostatic
motion [27,28]. This reduces the uncertainty of the lo-
cation of the prostate and allows treatment to be delivered
with a smaller treatment volume expansion, which may
reduce the doses delivered to the adjacent sexual structures.
Initial reports suggest that the incidence of ED following
SBRT is comparable to other radiotherapy modalities
[29]. The goal of this study is to report the sexual outcomes
following SBRT for clinically localized prostate cancer
in previously potent men.
Methods
Patient selection
Patients eligible for this study were those who had
histologically-confirmed prostate cancer and were potent
(patient-reported response of “firm enough for intercourse”
on Question 9 of the baseline EPIC-26) with or without
sexual aids prior to treatment. Patients who received ADT
were excluded from this study. Institutional IRB approval
was obtained for retrospective review of data that was
prospectively collected in our institutional database.
SBRT treatment planning and delivery
SBRT treatment planning and delivery were conducted
as previously described [30]. Briefly, gold fiducials were
placed into the prostate. Fused CT and MR images were
used for treatment planning. The clinical target volume
(CTV) included the prostate and the proximal seminal
vesicles. The planning target volume (PTV) equaled the
CTV expanded 3 mm posteriorly and 5 mm in all other
dimensions. The prescription dose was 35–36.25 Gy to
the PTV delivered in five fractions of 7–7.25 Gy over
one to two weeks. The PB (proximal portion of the cor-
pus spongiosum) was contoured [31] and evaluated with
dose-volume histogram analysis during treatment planning
using Multiplan (Accuray Inc., Sunnyvale, CA) inverse
treatment planning. The dose-volume histogram (DVH)
goal was for < 50% PB volume receiving 29.5 Gy. Assuming
an α/β of 3 Gy for late sexual complications, this is
Table 1 Baseline patient characteristics and treatment
Patients (n = 97)
Age (years) Age ≤ 60 14 (14.4%)
60 < Age ≤ 70 55 (56.7%)
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tered in 2 Gy fractions [32]. To minimize the risk of local
recurrence, the dose to the NVBs was not restrained.
Target position was verified during treatment using
paired, orthogonal x-ray images.
Follow-up and statistical analysis
Prostate-specific antigen (PSA) and total testosterone
levels were obtained before treatment and during routine
follow-up visits every 3 months for the first year and
every six months for the second year. Sexual function was
assessed with the Expanded Prostate Index Composite
(EPIC)-26 [7] and Utilization of Sexual Medication/Device
questionnaires at baseline and at all follow-ups. The EPIC-
26 sexual function domain includes five questions related
to sexual function and one question related to sexual
bother (degree of interference or annoyance caused by
limitations in sexual function) [33]. The sexual functions
assessed included quality of erection (potency), ability
to have erection, reliability of erections, ability to reach
orgasm and overall ability to function sexually. The def-
inition of potency and sexual activity were based on the
patient-reported response to Question 9 on the EPIC-26.
Potency was defined as the ability to have an erection
firm enough for intercourse [34] while sexual activity
was defined as the ability to have an erection firm
enough for masturbation and foreplay [4].
Student’s t-test and chi-square analysis were used to
assess differences in ongoing PSA, testosterone and quality
of life scores in comparison to baseline. Sample medians
and ranges were used to describe continuous variables
including PSA and testosterone. For each EPIC question,
the responses were grouped into two to three clinically
relevant categories. To statistically compare changes
between time points, the levels of responses were assigned
a score and the significance of the mean changes in the
scores was assessed by paired t test. EPIC scores for the
sexual domain and its individual questions range from
0–100 with lower values representing worsening sexual
symptoms. The minimally important difference (MID) in
EPIC score was defined as a change of one-half standard
deviation (SD) from the baseline [35]. To limit the effect
of attrition bias, statistical analysis was limited to time
points in which ≥ 80% of the patient data were available.
The impact of baseline patient characteristics on potency
rates two years post-SBRT were evaluated by univariate
Table 2 Quality of erection following SBRT for prostate cancer (patient-reported responses to question 9 of
the EPIC-26)
Follow up (months) Start 3 6 9 12 18 24
Firm enough for intercourse 100.0% 73.7% 67.8% 66.7% 62.2% 57.0% 54.4%
Firm enough for masturbation and foreplay only 0.0% 9.5% 18.4% 17.2% 17.8% 26.6% 23.3%
Not firm for any sexual activity 0.0% 16.8% 13.8% 16.1% 20.0% 16.5% 22.2%
p <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
Total patient 97 95 87 87 90 79 90
Table 3 Impact of baseline patient characteristics on
potency rates two years post-SBRT




≤ 65 y/o pre-RT 66.7% 0.580







Charlson comorbidity index (CCI)
0 58.9% 0.007*
≥1 35.3%
Body mass index (BMI)
< 30 60.9% 0.943
≥ 30 38.5%
Risk group (D’ Amico’s)












36.25 Gy 50.0% 0.933
< 36.25 Gy 55.0%
*Significant in univariate analysis; # Significant multivariate analysis.
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(ANOVA) was used to detect significant relationship
between patient characteristics and potency at 2 years
post treatment. In multivariate analysis, stepwise ordinal
logistic regression modeling was used to determine in-
dependent factors predicting sexual function outcome.
The baseline patient characteristics that were included
as variables in the univariate and multivariant analyses
included age, race, partner status, comorbidity, body mass
index (BMI), risk group, work status, Sexual Health Inven-
tory for Men (SHIM) score, erectile function and sexual
aid usage. All tests were two-tailed, and a p value <0.05
was considered significant. IBMW SPSS version 21 and
MedCalcW version 12.6.1.0 were used to perform the
statistical analyses.
Results
From February 2008 to March 2011, 216 prostate cancer
patients were treated per our institutional SBRT mono-
therapy protocol. Ninety-seven men who were identified
as being potent at the initiation of therapy and had a
minimal follow up of two years post-treatment were
included in this review (Table 1). They were ethnically
diverse with a median age of 66.8 years (range, 48–
82 years). The median pre-treatment total serum testoster-
one level was 11.4 nmol/L (range, 4.4 - 27.9 nmol/L). 43
patients were low-, 50 intermediate-, and 4 high-risk.
49.5% patients had ED prior to treatment (baseline
SHIM ≤ 21) with a median baseline SHIM of 22 (range,
3–25). 36.1% of patients were utilizing sexual aids prior
to SBRT. Phosphodiesterase 5 (PDE5) inhibitors were
utilized most commonly (36%) followed by vacuum de-
vices (1%). No patients utilized transurethral suppositories
or penile injections prior to treatment.
Ninety percent of patients were treated with 36.25 Gy
in five 7.25 Gy fractions (Table 1). The median follow-up
was 2.7 years. The median pre-treatment PSA of 5.9 ng/
ml declined to a median two years post-treatment of
0.5 ng/ml. There was one biochemical failure, occurring in
an intermediate-risk patient. The overall two-year actuarial
biochemical relapse free survival was 99%. No patient
initiated ADT in the first two years following therapy.
Erections sufficient for intercourse declined follow-
ing treatment: 100% (baseline); 67.8% (6 months); 62.2%
Table 4 Sexual aid utilization following SBRT for prostate
cancer
Sexual aid: Oral Vacuum Suppository Injection
Follow-up
Start 36.1% 1.0% 0.0% 0.0%
3 mon 35.8% 1.1% 1.1% 0.0%
6 mon 37.9% 2.3% 0.0% 0.0%
9 mon 39.1% 2.3% 0.0% 1.1%
12 mon 40.0% 4.4% 1.1% 0.0%
18 mon 45.0% 3.80025 1.3% 1.3%
24 mon 48.9% 3.8% 2.2% 2.2%
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(Table 2) which were statistically significant (p < 0.0001) at
all time points. The decline in potency at two years was
unlikely due solely to aging, as the average age of potent
patients (66.1 y/o) was not statistically different from
non-potent patients (68.0 y/o) (p = 0.17). However, at two
year post-SBRT, 77.8% of patients had erections that
were satisfactory for sexual activity including masturbation
and foreplay (Table 2). A Charlson Comorbidity Index
of ≥ 1 was significantly associated with a decreased prob-
ability of potency preservation at two years on univariate
(p = 0.007) , but was not significant on multivariate ana-
lysis (p = 0.246) (Table 3). Sexual aid usage prior to SBRT
was associated with an increased probability of potency
preservation two years following treatment on both uni-
variant (p = 0.010) and multivariant analysis (p = 0.037)
(Table 3). No other baseline patient characteristics were
significantly associated potency at two years followingFigure 1 Average EPIC sexual domain scores at baseline and followin
changes in scores (½ standard deviation above and below the baseline) ar
values representing a more favorable health-related QOL.SBRT. Two years post-treatment, overall sexual aid
utilization increased to 48.9%: oral medications (48.9%),
vacuum device (6.7%), urethral suppository (2.2%) and
penile injection (2.2%) (Table 4). No men utilized a
penile prosthesis.
Adequate sexual function involves more than just pos-
sessing adequate erections [36]. The EPIC sexual domain
allows for a more comprehensive and reliable assessment
of a patients overall sexual function [37]. Average EPIC
sexual scores showed a slow decline over the first two
years following treatment: 77.6 (baseline); 68.7 (6 months);
63.2 (12 months); 61.9 (18 months); 59.3 (24 months)
(Figure 1). At two year post-treatment, this change was
statistically (p < 0.001) and clinically significant (Figure 1).
All sexual functions including orgasm declined with time
in a similar manner (Figure 2a, d, Table 5).
Sexual bother may be more important to an individual
patient than sexual function. As for the overall EPIC
sexual domain scores, post-SBRT sexual bother scores
were significantly lower than pre-SBRT scores at all time
points (Figure 3, Table 6). The proportion of men feeling
that their sexual function was a moderate to big problem
increased from 13.4% to 30% at 18 months post-SBRT
(Figure 3, Table 6).
Pre-treatment total serum testosterone levels ranged
from 4.4 nmol/L to 27.9 nmol/L with a median value of
11.4 nmol/L. 24.7% of patients were hypogonadal (total
serum testosterone level below 8 nmol/L) prior to SBRT.
At two years the median serum testosterone value of
10.7 nmol/L (range, 2.5- 26.4 nmol/L) was not significantly
lower than the pre-treatment value (p = 0.07) (Figure 4a).
The median absolute reduction was small (0.7 nmol/L)g SBRT for prostate cancer. Thresholds for clinically significant
e marked with dashed lines. EPIC scores range from 0–100 with higher
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treatment and 2-year post SBRT biochemical hypo-
gonadism rates were not significantly different (data
not shown). At one month post-treatment, the mean
EPIC hormone score declined to 93.5 from a baseline
of 95.6 (p = 0.04); it returned to baseline by 6 months
post-treatment (Figure 4b).
Similar to prior reports, the median PB volume in this
series was 11 cc [31]. The mean percentage of the PB
receiving 29.5 Gy was 7.0% (range: 0–32.7%), with the
potent and impotent groups receiving 6.3% (SD 6.5%)
and 7.2% (SD 8.6%), respectively. The four patients who
received 29.5 Gy to > 25% of the PB were impotent two
years following treatment.
Discussion
Erectile dysfunction following prostate radiation therapy
remains an ongoing challenge and critical quality of life
issue [1]. Currently, there is limited data on sexual out-
comes following SBRT for prostate cancer [29]. A betterFigure 2 Average individual EPIC sexual function scores at baseline a
erection-Question 8A of the EPIC-26; (b) ability to reach orgasm- Question
(d) ability to function sexually- Question 11 of the EPIC-26. Thresholds for c
below the baseline) are marked with dashed lines. EPIC scores range from
health-related QOL.understanding of the sexual declines following SBRT
would enable clinicians to provide more realistic expec-
tations to patients as they weigh the complex treatment
options [10]. Our prior report on sexual function follow-
ing SBRT [30] utilized the SHIM questionnaire which
primarily focuses on erectile function and is an inad-
equate measure of overall sexual function [5,36]. In this
study, we utilized the EPIC-26 sexual function domain to
evaluate erectile function but also assess overall sexual
function including orgasmic function and sexual bother.
For this analysis, potency was rigorously defined as the
ability to have an erection firm enough for intercourse
[4]. Forty five percent of our patients were potent prior
to SBRT and these patients were included in this analysis.
Still, they were elderly with relatively low baseline
SHIM scores and high pretreatment sexual aid utili-
zation (Table 1). Even so, two years post-SBRT, 54% of
these patients remained potent and 78% maintained an
erection firm enough for masturbation and foreplay.
As seen previously, the greatest decline in potencynd following SBRT for prostate cancer. (a) ability to have an
8B of the EPIC-26; (c) reliability of erection- Question 10 of the EPIC-26;
linically significant changes in scores (½ standard deviation above and
0–100 with higher values representing a more favorable
Table 5 Sexual functions following SBRT for prostate cancer: patient-reported responses to EPIC-26 questions 8A
(ability to have an erection), 8B (ability to reach orgasm), 10 (reliability of erections) and 11 (ability to function sexually)
Start 3 6 9 12 18 24
Ability to have an erection
Very good-good 58.8% 51.6% 56.3% 43.7% 45.6% 41.8% 36.7%
Fair 34.0% 33.7% 26.4% 26.4% 25.6% 29.1% 31.1%
Poor, very poor and none 7.2% 14.7% 17.2% 29.9% 28.9% 29.1% 32.2%
p <0.04 <0.140 <0.001 <0.001 <0.001 <0.001
Ability to reach orgasm
Very good-good 74.2% 56.8% 63.2% 51.7% 53.3% 53.2% 46.7%
Fair 18.6% 27.4% 18.4% 24.1% 24.4% 22.8% 25.6%
Poor, very poor and none 7.2% 15.8% 18.4% 24.1% 22.2% 24.1% 27.8%
p <0.05 0.089 <0.003 <0.001 <0.001 <0.001
Reliability of erections
More than half-half the time 78.4% 66.3% 64.4% 55.2% 57.8% 54.4% 52.2%
Less than half the time 21.6% 33.7% 35.6% 44.8% 42.2% 45.6% 47.8%
p <0.004 <0.003 <0.001 <0.001 <0.001 <0.001
Function sexually (overall)
Very good-good 63.9% 53.7% 52.9% 47.1% 47.8% 43.0% 40.0%
Fair 33.0% 29.5% 28.7% 24.1% 25.6% 24.1% 30.0%
Poor-very poor 3.1% 14.7% 16.1% 28.7% 26.7% 32.9% 30.0%
p <0.003 <0.005 <0.001 <0.001 <0.001 <0.001
N= 97 95 87 87 90 79 90
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with stabilization afterwards [38]. These results are
comparable to results with conventionally fractionated
EBRT or brachytherapy [2,10,29].
The etiology of this early decline in potency is unclear
but may involve exposure of the NVBs, crura or PBFigure 3 EPIC sexual bother at baseline and following SBRT for prost
scores. Thresholds for clinically significant changes in scores (½ standard de
EPIC scores range from 0–100 with higher values representing a more favoto excessive radiation. In this series, which included
patients with unfavorable cancers, there was no attempt
to spare the NVBs due to the concern that this may
cause an unacceptably high rate of local failures [39].
Post-treatment sexual dysfunction may be exacerbated
by high PB doses. With the aim of improving potency,ate cancer- Question 12 of the EPIC-26. Average sexual bother
viation above and below the baseline) are marked with dashed lines.
rable health-related QOL.
Table 6 Sexual brother following SBRT for prostate cancer (patient-reported responses to question 12 of the EPIC-26)
Sexual brother Start 3 mon 6 mon 9 mon 12 mon 18 mon 24 mon
No problem 47.42% 40.86% 42.53% 37.93% 41.11% 41.25% 38.89%
Very small-small problem 39.18% 40.86% 34.48% 40.23% 36.67% 28.75% 34.44%
Moderate-big problem 13.40% 18.28% 22.99% 21.84% 22.22% 30.00% 26.67%
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the PB dose, we have restricted the PB dose to < 25% of
the volume receiving 29.5 Gy. Utilizing SBRT, this was
easily achievable. PB doses below this did not correlate
with impotence. We believe that such modifications
have the potential to reduce the incidence and severity of
impotence without increasing the risk of local failure.
Declining potency following SBRT suggests a need for
approaches to improving long-term sexual outcomes. In
this study, pre-treatment sexual aid usage was associated
with increased potency two years following SBRT. Sexual
aid utilization increased from a baseline of 37% to 49%
at 24 months. Oral medication usage was common but
vacuum device, urethral suppository, penile injection and/
or penile prosthesis were rarely utilized. It is not clear
why post-treatment utilization of these potentially effective
therapies [10] was not higher. Possible explanations
include patient’s perception of potential discomfort, the
high cost of such treatments or partner availability.
Others have shown that while sexual function may be
improved by the use of sexual aids, sexual bother may
be enhanced [33].
Like other treatment modalities, this study shows that
SBRT impacts all areas of sexual function including
erections, orgasm and overall satisfaction [40,41]. For
example, only 46.7% of men two years following SBRT
reported at least a good ability to reach orgasm com-
pared to 74% prior to treatment (Table 5). The etiology
of this decline in the ability to obtain orgasm is unclear
but could be related to hemospermia, reduced ejaculateFigure 4 Pre- and post-treatment testosterone levels and EPIC hormo
p values were from χ2-analysis with baseline testosterone levels. (b) Averag
scores (½ standard deviation above and below the baseline) are marked w
representing a more favorable health-related QOL.and/or painful ejaculation [42-45]. To better assess the
etiology of orgasmic dysfunction, our future studies will
employ an instrument to assess the effect of SBRT on
ejaculation [46].
Bother may be a better indicator than function on
how a treatment impacts an individual patient’s quality
of life [47]. Sexual bother is defined as the degree of
interference or annoyance caused by limitations in sexual
function and is dependent on an individual’s pre-treatment
erectile function, libido and partner status [33]. In general,
previously potent men report a higher rate of bother
following treatment than impotent men [48]. In this
series of potent men, sexual bother slowly increased
during the first two years following SBRT treatment
(Figure 3, Table 6). Similar to other radiation modalities,
this rate plateaued at 12–24 months following treatment
with 30-40% of men reporting sexual bother as a moderate
to big problem [2,49]. As in other series, sexual bother
scores were better than sexual function scores.
Our study has several limitations. The penile bulb may
not be the critical component of the erectile apparatus,
but may be a surrogate for the crura in conventional
radiation therapy treatment planning [16]. The utilization
of non-coplanar beams in SBRT treatment could yield
unexpectedly high doses to the crura [50]. Future studies
should determine the crura dose during SBRT treatment
and its impact on post-SBRT potency. In addition, the
pretreatment utilization of sexual aids in our patients
was high compared to previous reports [29]. The etiology
is unclear but may limit the generalizability of this study.nal scores. (a) Box-and-Whisker plot of total testosterone levels. The
e EPIC hormonal scores. Thresholds for clinically significant changes in
ith dashed lines. EPIC scores range from 0–100 with higher values
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SBRT was well-tolerated for these patients with clinically
localized prostate cancer. Men with preserved potency
undergoing SBRT monotherapy for prostate cancer have
sexual outcomes comparable to those reported for alterna-
tive radiation modalities within the first 24 months after
treatment. Although most men retained sexual function,
declining potency following treatment suggest a need for
new approaches to improve long-term sexual outcomes.
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